Nerve growth factor causes epinephrine release dysfunction by regulating phenotype alterations and the function of adrenal medullary chromaffin cells in mice with allergic rhinitis
Molecular Medicine Reports · 02.01.2023 · 27 (2)
DOI: 10.3892/mmr.2023.12926 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Medicine Reports, online erschienen am 02.01.2023. Verfasst von Chao Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Disease, Zhongshan People's Hospital, Zhongshan, Guangdong 528403, P.R. China. Hauptthemen laut MEDLINE: Asthma, Rhinitis, Allergic, Chromaffin Cells. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The presence of allergic rhinitis (AR) is an increased risk factor for the occurrence of bronchial asthma (BA). Nerve growth factor (NGF), in addition to its key role in the development and differentiation of neurons, may also be an important inflammatory factor in AR and BA. However, the pathogenesis of the progression of AR to BA remains to be elucidated. The present study aimed to investigate the ability of NGF to mediate nasobronchial interactions and explore possible underlying molecular mechanisms. In the present study, an AR mouse model was established and histology of nasal mucosa tissue injury was determined. The level of phenylethanolamine N‑methyl transferase in adrenal medulla was determined by immunofluorescence. Primary adrenal medullary chromaffin cells (AMCCs) were isolated and cultured from the adrenal medulla of mice. The expression levels of synaptophysin (SYP), STAT1, JAK1, p38 and ERK in NGF‑treated and untreated AMCCs were detected by reverse‑transcription‑quantitative PCR and western blotting. The epinephrine (EPI) and norepinephrine (NE) concentrations were measured by ELISA. It was found that the expression of SYP in AMCCs was enhanced in the presence of NGF, whereas, the concentration of EPI decreased significantly under the same conditions. Furthermore, NGF mediated the phenotypic and functional changes of AMCCs, resulting in decreased EPI secretion via JAK1/STAT1, p38 and ERK signaling. In conclusion, these findings could provide novel evidence for the role of NGF in regulating neuroendocrine mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Disease, Zhongshan People's Hospital, Zhongshan, Guangdong 528403, P.R. China.
- Dental Implant and Restoration Centre, Zhongshan People's Hospital, Zhongshan, Guangdong 528403, P.R. China.
- Department of Respiratory Disease, Ji'an First People's Hospital, Ji'an, Jiangxi 343099, P.R. China.
- The Second Department of Respiratory Disease, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi 330006, P.R. China.
Zitieren
APA
Liu, C., Liang, J. P., Huang, X. L., Liu, Z., Zhang, A. B., Deng, N. G., Wei, Z. F., & Wang, J. (2023). Nerve growth factor causes epinephrine release dysfunction by regulating phenotype alterations and the function of adrenal medullary chromaffin cells in mice with allergic rhinitis. Molecular Medicine Reports, 27(2). https://doi.org/10.3892/mmr.2023.12926
Vancouver
Liu C, Liang JP, Huang XL, Liu Z, Zhang AB, Deng NG, et al. Nerve growth factor causes epinephrine release dysfunction by regulating phenotype alterations and the function of adrenal medullary chromaffin cells in mice with allergic rhinitis. Molecular Medicine Reports. 2023;27(2). doi:10.3892/mmr.2023.12926
BibTeX
@article{Liu2023,
author = {Liu, Chao and Liang, Jian-Ping and Huang, Xiao-Lin and Liu, Zhong and Zhang, An-Bing and Deng, Nian-Gen and Wei, Zi-Feng and Wang, Jun},
title = {Nerve growth factor causes epinephrine release dysfunction by regulating phenotype alterations and the function of adrenal medullary chromaffin cells in mice with allergic rhinitis},
journal = {Molecular Medicine Reports},
year = {2023},
volume = {27},
number = {2},
doi = {10.3892/mmr.2023.12926}
}
EUVIMED